Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | — |
The patient took the Vivotif vaccine on days 1,3,6 and 8 instead of on days 1,3,5, and 7; Case reference number US-BN-2025-001814 is a spontaneous case initially received from a pharmacist via Bavarian Nordic (reference number: CASE-000808) on 18-Nov-2025 and concerns a 18-years-old male patient. The patient's medical history and concomitant medications details were provided. On an unspecified date, reported as on day one, the patient received the first dose of Vivotif vaccine (batch number: unknown), at unknown dose, route or site of administration for unknown indication. On an unspecified date, reported as on day three, the patient received the second dose of Vivotif vaccine (batch number: unknown), at unknown dose, route or site of administration. On an unspecified date, reported as on day six, the patient received the third dose of Vivotif vaccine (batch number: unknown), at unknown dose, route or site of administration (explicitly coded as 'inappropriate schedule of vaccine administration'). On an unspecified date, reported as on day eight, the patient received the fourth dose of Vivotif vaccine (batch number: unknown), at unknown dose, route or site of administration (explicitly coded as 'inappropriate schedule of vaccine administration'). At the time of initial report, it was unknown if the patient experienced any adverse event due to Viviotif vaccine. No further information was provided.; Reporter's Comments: An 18-year-old male patient received the third and the fourth dose of Vivotif for unknown indication on the days 6 and 8, which is considered as inappropriate schedule of vaccine administration. It was unknown if the patient experienced any adverse event due to Viviotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications details were provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An 18-year-old male patient received the third and the fourth dose of Vivotif for unknown indication on the days 6 and 8, which is considered as inappropriate schedule of vaccine administration. It was unknown if the patient experienced any adverse event due to Viviotif vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medications details were provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.